60 Degrees Pharmaceuticals, Inc. (SXTP)
$0.90-2.17%Close
SELLCRISIS · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $725,895
- Beta
- 2.40
- P/E (TTM)
- -0.15
- Short % float
- 17.07%
- Days to cover
- 1.6
- SI change
- -38.3%
- 1W
- -18.92%
- 1M
- +0.00%
- vs SPY 1W
- -19.34%
- vs SPY 1M
- -2.06%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 8
- GROWTH
- 32
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-127.0%
REV YoY-
ROE-211.6%
EPS YoY-
ROA-189.4%
GROSS19
OP-775
NET-730
[VALUATION]
P/E TTM-0.15
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.91
P/FCF-
EV/EBITDA-0.29
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E5.78
ALTMAN Z-
CURR RATIO2.32
ND/EBITDA-
BETA2.40
Company news
FAQ
- What is LOPJLB’s current signal on SXTP?
- LOPJLB’s latest quantitative signal on 60 Degrees Pharmaceuticals, Inc. (SXTP) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SXTP in?
- 60 Degrees Pharmaceuticals, Inc. (SXTP) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does 60 Degrees Pharmaceuticals, Inc. (SXTP) do?
- 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is …